NEWS
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
Chromocell Therapeutics (NYSE American: CHRO) has unveiled an injectable depot program using peripheral nerve blocks for post-operative pain treatment. The program leverages the company's NaV1.7 molecule, targeting a market of approximately 700,000 total knee replacements and 500,000 shoulder arthroplastiesperformed annually in the US. The company's drug has shown no addictive properties in four Phase I trials and demonstrated strong efficacy in preclinical models. The program aims to reduce opioid usage and could benefit from NOPAIN Act provisions upon FDA approval.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2544Followers
107Following
28KVisitors
Follow